Tensions are reportedly rising behind the scenes at Old Trafford as the Glazer family grow increasingly frustrated with Sir Jim Ratcliffe's leadership. Despite the INEOS founder taking control of football operations earlier this year, the club has slumped to its worst start to a league campaign in nearly four decades.
Ratcliffe acquired a minority stake in United in 2024, a deal worth £1.2 billion that handed his INEOS group total control over football operations. The agreement included an additional £245 million injection to upgrade Old Trafford's fading infrastructure, taking his overall financial commitment to approximately £1.5bn. However, two years on, the anticipated revival has failed to materialise.
Instead of progressing, the Red Devils find themselves embroiled in a deepening crisis. They are currently enduring an eight-game winless run across all competitions, managing just a single Premier League victory so far this term. Hovering a perilous two points above the foot of the table, this represents United's poorest start to a campaign in almost 40 years.
Watching from afar, the Glazer family are reportedly astonished by the rapid decline under the new sporting regime. A source close to the American owners told the Daily Mail that the current situation is "a travesty and not what they expected or were promised." The insider added that the Glazers feel "they have never run the club this way."
The frustration runs deep, with the current hierarchy allegedly viewing the INEOS approach as a complete failure. According to ESPN, the Glazers believe Ratcliffe "couldn't have masterminded a worse situation" at Old Trafford.

#league

The Week 10 Houston-area and statewide Texas high school football scores from Thursday's games as compiled by the ******* ociated Press.
Cypress Falls 41, Cypress Ridge 0
Cypress Ranch 62, Richmond Foster 27
Dickinson 49, Clear Falls 24
Dallas South Oak Cliff 49, Dallas Jefferson 0

#falls #houston #associated

Jaylen Brown's talk with Daniel Radcliffe offered lessons beyond basketball appeared first on ClutchPoints. Add ClutchPoints as a Preferred Source by clicking here.
Jaylen Brown had plenty to say about basketball during his conversation with Daniel Radcliffe. The more interesting question, however, concerned how much power he plans to give everyone who talks about him.
Across discussions about personal recognition, public criticism, and Harry Potter, the Philadelphia 76ers forward returned to a consistent idea: Other people can judge him, but he gets to decide which judgments deserve his attention.
That distinction gave their October 29 podcast appearance substance beyond the unexpected pairing. Brown offered an approach to ambition that leaves room for achievement without making approval the ultimate destination.
Watch sports LIVE with fuboTV (free trial)

#brown #preferred

Procter & Gamble has raised its dividend for 70 straight years while Johnson & Johnson covers its roughly $12.6 billion dividend run rate 1.56 times with free cash flow.
Coca-Cola posted its strongest Trademark volume growth in 17 years, and ADP's operating cash flow covers its dividend more than twice over while still funding buybacks.
Lowe's carries the lowest payout ratio in the group at 41% and trades at just 15 times earnings after falling 24% year to date.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
Yield is relatively easy to find. A dividend that keeps arriving through recessions, patent cliffs and housing slumps is much harder to find, and that kind of reliability is the hook for this group. Every name below covers its payout with real cash flow, has a long record of raises and keeps its payout ratio at a level that leaves room for mistakes. Procter & Gamble (NYSE:PG) sets the standard: management says its latest increase marks the 70th consecutive year of dividend increases and 136th consecutive year of dividend payments, putting it firmly in the Dividend Kings club (we ranked ten of them by valuation in a free report here). The other four pair long dividend records with cash flow that covers the payout.

#cash #year #procter #gamble

Megan Thee Stallion had one tiny problem while filming with Daniel Radcliffe: She kept seeing Harry Potter. The rapper admitted she struggled to separate Radcliffe from his iconic role while filming NBC's The Fall and Rise of Reggie ****** ins.
The unexpected fangirl moment came during a packed year for Megan. Alongside her acting work, she made her Broadway debut, navigated a breakup, and continued shaping her delayed Act III album.
Megan discussed the experience in a new interview with Marie Claire. She played Denise, a divorced mail carrier who developed a flirtation with Radcliffe's documentary filmmaker character, Arthur Tobin. "I was on that set, calling that man Harry Potter all day," Megan admitted.
Radcliffe apparently took the teasing well. Megan said their easy friendship helped create their chemistry onscreen. "Daniel made me feel so, so, so comfortable," she said. "We were literally talking and joking the whole time. I think that's why the chemistry was so good." Radcliffe returned the compliment, praising Megan's willingness to jump into acting. "We were honestly so lucky to get Megan to be on the show," he said.
He added that guest stars of her stature usually took longer to join established shows. Radcliffe called her "a total pro, a delight to work with, and really ****** funny." The role added another credit to Megan's expanding acting résumé. She also appeared in She-Hulk: Attorney at Law, Big Mouth, ****** s: The Musical and Mean Girls.

#daniel #harry #potter #filming

Celebrity birthdays for the week of Oct. 11-17:
Oct. 11: Country singer Gene Watson is 83. Singer Daryl Hall of Hall and Oates is 80. Actor Catlin Adams ("The Jerk," "The Jazz Singer") is 76. Country singer Paulette Carlson (Highway 101) is 75. MTV VJ Mark Goodman is 74. Actor David Morse ("St. Elsewhere") is 73. Actor Stephen Spinella ("24") is 70. Actor Joan Cusack is 64. Guitarist Scott Johnson of Gin Blossoms is 64. Actor-writer Michael J. Nelson ("Mystery Science Theater 3000") is 62. Actor Sean Patrick Flanery is 61. Actor Lennie James ("The Walking Dead") is 61. Musician Todd Snider is 60. Actor Artie Lange ("MADtv") is 59. Actor Jane Krakowski ("30 Rock," "Ally McBeal") is 58. Actor Andrea Navedo ("Jane the Virgin") is 57. Rapper MC Lyte is 56. Actor Constance Zimmer ("UnREAL," "Agents of S.H.I.E.L.D.") is 56. Actor Darien Sills-Evans ("Superior Donuts," "Treme") is 52. Singer NeeNa Lee is 51. Actor Emily Deschanel ("Bones") is 50. Actor Trevor Donovan ("90210") is 48. Rapper Cardi B is 34.
Oct. 13: Gospel singer Shirley Caesar is 89. Musician Paul Simon is 85. Keyboardist Robert Lamm of Chicago is 82. Country singer Lacy J. Dalton is 80. Singer Sammy Hagar is 79. Singer John Ford Coley of England Dan and John Ford Coley is 78. Model Beverly Johnson is 74. Actor John Lone ("The Last Emperor," "Rush Hour 2") is 74. "The X-Files" creator Chris Carter is 70. Singer Cherrelle is 67. Singer-actor-talk show host Marie Osmond is 67. Singer Joey Belladonna of Anthrax is 66. Actor T'Keyah Crystal Keymah ("That's So Raven," "In Living Color") is 64. Country singer John Wiggins is 64. Actor Christopher Judge (TV's "Stargate SG-1") is 62. Actor Matt Walsh ("Veep") is 62. Actor Reginald Ballard ("Martin," "The Bernie Mac Show") is 61. Actor Kate Walsh ("Private Practice," "Grey's Anatomy") is 59. Musician Jeff Allen of Mint Condition is 58. Actor Tisha Campbell-Martin ("My Wife and Kids," "Martin") is 58. Country singer Rhett Akins is 57. TV personality Billy Bush is 55. Actor Sacha Baron Cohen ("Borat," "Da Ali G Show") is 55. Guitarist Jan Van Sichem Jr. of K's Choice is 54. Singers Brandon and Brian Casey of Jagged Edge are 51. Actor Kiele Sanchez ("Lost") is 50. Singer Ashanti is 46. Singer-rapper Lumidee is 46. Contemporary Christian singer Jon Micah Sumrall of Kutless is 46. Actor Caleb McLaughlin ("Stranger Things") is 25.
Oct. 14: Director Carroll Ballard ("The Black Stallion") is 89. Singer Cliff Richard is 86. Singer Justin Hayward of the Moody Blues is 80. Actor Greg Evigan ("My Two Dads," "B.J. and the Bear") is 73. Singer Thomas Dolby is 68. Actor Lori Petty ("A League of Their Own") is 63. Actor Steve Coogan ("Night at the Museum" movies) is 61. Singer Karyn White is 61. Actor Edward Kerr ("Pretty Little Liars," "Snoops") is 60. Actor Jon Seda ("Chicago P.D.," "Homicide: Life on the Street") is 56. Bassist Doug Virden (Sons of the Desert) is 56. Country singer Natalie Maines of The Chicks is 52. Singer Shaznay Lewis of All Saints is 5

Joe Evermore's 7-year-old son climbed El Capitan in Yosemite National Park, making him the youngest person to ever accomplish such a feat
But in posts celebrating the achievement, many in the comments take issue with the risk involved in taking on such a climb with young children
"There's a lot of bullying that goes on online," Joe tells PEOPLE in an interview
Joe Evermore knows not everyone agrees with his parenting style.
He and his wife, Ann, have made a name for themselves online for sharing their family's impressive climbs — including El Capitan in Yosemite National Park, the largest granite cliff in the world, which their 7-year-old son completed in May, making him the youngest person to ever accomplish such a feat. But in posts celebrating the achievement, many in the comments take issue with the risk involved in taking on such a climb with young children.

#capitan

MrBeast, whose real name is Jimmy Donaldson, put dozens of strangers through one of his outrageous tests: How long can people stay in a grocery store to win $250,000? One contestant, Juan Garcia, managed to do it and took home far more than he bargained for after spending over 200 days in the store.
Back in April, MrBeast uploaded a video to his channel ******* led "Last to Leave Grocery Store, Wins $250,000," and in the months since, the video racked up over 200 million views.
At the start of the video, MrBeast tells his audience he just bought a grocery store and uses the store's intercom to announce that the last person to leave wins the $250,000 prize pot (kept in a comically large gold shopping cart). Some shoppers immediately left with a bounty of groceries that MrBeast told everyone were free; others began to strategize, building forts and stockpiling food.
After 67 days, with only four contestants left, MrBeast decided to shake things up and gave them an ultimatum: If they decided to stay, he'd restock the entire grocery store, and the four of them had to eat all the groceries – if they were able to do so, they could split a $1,000,000 prize. They decided to stay, and the video ended on a cliffhanger, leaving fans wondering where the new video would be for months.
Today, MrBeast and his team finally released the second part, ******* led "Eat Everything In A Grocery Store Win $1,000,000."

#grocery #stay #decided #wins

Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule for Wegovy and Ozempic, generates roughly 75% of 2026 revenue. Morgan Stanley models that it will still represent 59% of total sales when its patent protection expires in 2031. And according to the firm, the valuation does not price in the impact it has on Novo's terminal value. The stock, currently trading at 10.6x earnings and down 33% from its 52-week high, slipped another 2% following the call. At this point, the question isn't about whether the patent cliff is real or not, but whether the 10x multiple reflects an actual bargain.
Semaglutide loses exclusivity in Europe in 2031 and the US in 2032. And Morgan Stanley believes Novo's oral-obesity business, projected to reach $10 billion by 2031, could not offset the pricing collapse after the arrival of generics. Growth decelerates to a 4% compound rate between 2027 and 2030. If the deceleration continues, it will justify 10x earnings as a fair price instead of a cheap one.
The 10.6x multiple already prices aggressive pessimism into a market leader of one of the fastest-growing drug classes in history. Morgan Stanley fueled the pessimism by discounting a 2031 cliff five years earlier. However, pharmaceutical patent expirations frequently face extensions and prove difficult to time. Second, the ***** umption that oral obesity treatments cannot offset patent losses relies on oral semaglutide being the bridge. But Novo's next-generation portfolio, including CagriSema and amycretin, offers a significant defense against the patent cliff. This remains unproven, however, specifically after CagriSema's earlier weight-loss data failed to impress, yet Morgan Stanley's terminal-value model discounts this pipeline almost entirely. The company is also expanding its franchise. On September 7, the STEP Young trial hit its endpoint in children aged six to twelve, strengthening the base its successors inherit.
The smart money is leaning in. As per the Insider Monkey database, 59 hedge funds held NVO in the second quarter of 2026, up from 55 in the first, indicating a slight increase in the modest institutional interest in the stock. Short interest on the ADR is negligible at about 0.7%. The positioning reflects a beaten-down value stock quietly seeing institutional accumulation while Wall Street turns increasingly bearish.

#semaglutide #oral

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
Revenue over the trailing twelve months was $66.6 billion, up 4.6% and in line with its own three-year pace. Profitability did not follow. Its operating margin over the same twelve months was 10.5%, versus a three-year average of 22.4%.
Most of that gap is one purchase. Merck took a $5.7 billion charge in the second quarter of 2026, about 9% of a year's sales. It bought Terns Pharmaceuticals, and with it MK-4208, a candidate for chronic myeloid leukemia. The bill hits earnings now and the medicine arrives later.
The proof matters because of the risk hanging over this stock. The KEYTRUDA family was just over half of Merck's revenue in the second quarter of 2026. The company is openly planning for the end of that exclusivity when Keytruda loses primary U.S. patent protection in 2028. Management describes the stretch as more of a hill than a cliff, with a shallow dip and a fast return to growth.
Johnson & Johnson (JNJ) returned 56% over the same twelve months and Pfizer (PFE) 23%, so a good year for pharmaceuticals explains some of this but not Merck's lead. What separated Merck was evidence. The FDA approved LIPFENDRA, the first and only oral PCSK9 inhibitor. In the CORALreef Lipids trial it lowered LDL cholesterol by up to 60% when added to a statin.

#year #johnson

Amgen (AMGN) yields 2.6% with a $10.08 annualized payout, topping Merck (MRK) at 2.29%, and has raised its dividend 6% annually versus Merck's smaller step-ups.
Amgen's 17 billion-dollar products and $3.5B quarterly free cash flow dwarf Merck's reliance on a single Keytruda franchise facing peak penetration.
Merck absorbed a $5.7B acquisition charge that pushed Q2 earnings to a loss, while Amgen raised 2026 EPS guidance to as high as $23.50.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Enter your email to see the names that beat MRK. The report is free. Enter your email and see if any of your stocks made the cut.
For a retirement portfolio that leans on pharma dividends, the choice between Amgen (NASDAQ:AMGN) and Merck (NYSE:MRK) comes down to one question: which check is more likely to keep getting bigger through the next wave of patent expirations? Both companies deliver quarterly income today. Only one has the coverage, the growth cadence, and the portfolio breadth to keep raising through the cliff.

#merck #amgen

Steel and materials markets fluctuated between rallies and pullbacks as the US-Canada trade relationship shifted from near agreement to open dispute. Nucor Corporation (NYSE:NUE) and Cleveland-Cliffs Inc. (NYSE:CLF) rose on August 25, after discussions between the two countries broke down, a turnaround from the week before, when several of the same stocks fell on hopes that a new deal would decrease steel and aluminum tariffs. The VanEck Steel ETF gained 1.6% on the day, while the State Street Materials Select Sector SPDR reached an intraday high. The rise didn't last: by the end of the week, the materials ETF had slipped to negative territory, while the steel ETF was about flat, though, both remain substantially up for 2026.
The volatility traces a rapid escalation. On August 19, Bloomberg reported that the US and Canada had tentatively agreed to reduce tariffs on Canadian steel and aluminum to 25% and vehicle charges to 15%. That optimism was dashed within days: on August 22, the US imposed 50% tariffs on a wide variety of Canadian exports, and Canadian Prime Minister Mark Carney responded by declaring Canada officially "at war" with the United States, saying "You're at war when you're attacked, and we got attacked."
On August 25, Ottawa announced counter-tariffs of C$27.6 billion on American goods, which took effect on September 8 at rates ranging from 15% to 50%. The dispute has continued to escalate since then, with Washington announcing additional restrictions and tariffs on Canadian goods in September, reinforcing the view that a quick resolution remains unlikely.
Atsi Sheth, Moody's chief credit officer, put it bluntly: "Expect much more of this uncertainty for some time to come." Investors initially welcomed tariffs as good news for US steelmakers facing less Canadian competition, but the back-and-forth negotiations, as well as Canada's reaction, have made predicting a steady outcome difficult.
The more intriguing story is how differently the aforementioned companies are positioned. Nucor Corporation (NYSE:NUE) relies primarily on scrap-based electric arc furnace steelmaking, while Cleveland-Cliffs Inc. (NYSE:CLF) operates a vertically integrated model with internally sourced iron ore, scrap and other raw materials. Both have meaningful domestic raw-material exposure, although their production models differ substantially. Nucor Corporation (NYSE:NUE) is up more than 50% year-to-date, while Cleveland-Cliffs Inc. (NYSE:CLF), despite similar structural insulation, remains negative for 2026, which **** ysts attribute to balance sheet stress rather than tariffs.

#august #nucor #corporation #cleveland

Novo Nordisk A/S (NYSE:NVO)'s decision to rebrand its day-to-day identity as "Novo" and launch a cultural reset is primarily a strategic response to the company's loss of momentum in the obesity-drug market, rather than a financial restructuring in itself. Reuters reports that the company is trying to regain competitiveness as pressure from Eli Lilly intensifies. The move comes as Novo prepares to unveil new strategic ambitions at its September 21 Capital Markets Day, making the cultural reset potentially important if it leads to faster decision-making, stronger commercial execution and a more aggressive R&D approach.
The underlying business still has substantial scale to protect. Novo generated DKK 309.1 billion of 2025 sales and DKK 127.7 billion of operating profit, while obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion. However, the company also spent around DKK 8 billion on its transformation in 2025, and its diabetes value-market share fell 3.6 percentage points to 30.1%. The reset therefore comes at a critical point: Novo remains the global obesity-market leader, with a 59.6% branded-volume share in 2025, but Lilly is rapidly narrowing the competitive gap.
A successful cultural reset could improve Novo Nordisk A/S (NYSE:NVO)'s execution at a time when the company needs to convert its scientific and commercial ******* ets into faster growth. Reuters reported that CEO Mike Doustdar is already seeking to accelerate R&D and streamline decision-making following investor concerns about the pipeline and competition from Lilly. If the reorganization reduces internal bureaucracy and improves the speed of clinical, regulatory and commercial decisions, it could help Novo extract more value from its existing obesity portfolio while advancing next-generation treatments before the semaglutide patent cliff expected early next decade.
The company also has ******* ets that give a cultural and operational reset something concrete to build around. Wegovy was available in 52 countries by the end of 2025, while the company's higher-dose Wegovy achieved 20.7% weight loss in Phase 3 studies and its oral Wegovy achieved 16.6% weight loss. More recently, Wegovy received approval in China for MASH, expanding its potential beyond weight management and cardiovascular benefits into another large metabolic-disease market. If Novo Nordisk A/S (NYSE:NVO) can combine these products with better execution, the reset could support higher patient volumes and extend the commercial life of its GLP-1 franchise, helping defend revenue and cash flow despite pricing pressure.

#nordisk #lilly

Novo Nordisk A/S (NYSE:NVO)'s decision to rebrand its day-to-day identity as "Novo" and launch a cultural reset is primarily a strategic response to the company's loss of momentum in the obesity-drug market, rather than a financial restructuring in itself. Reuters reports that the company is trying to regain competitiveness as pressure from Eli Lilly intensifies. The move comes as Novo prepares to unveil new strategic ambitions at its September 21 Capital Markets Day, making the cultural reset potentially important if it leads to faster decision-making, stronger commercial execution and a more aggressive R&D approach.
The underlying business still has substantial scale to protect. Novo generated DKK 309.1 billion of 2025 sales and DKK 127.7 billion of operating profit, while obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion. However, the company also spent around DKK 8 billion on its transformation in 2025, and its diabetes value-market share fell 3.6 percentage points to 30.1%. The reset therefore comes at a critical point: Novo remains the global obesity-market leader, with a 59.6% branded-volume share in 2025, but Lilly is rapidly narrowing the competitive gap.
A successful cultural reset could improve Novo Nordisk A/S (NYSE:NVO)'s execution at a time when the company needs to convert its scientific and commercial ***** ets into faster growth. Reuters reported that CEO Mike Doustdar is already seeking to accelerate R&D and streamline decision-making following investor concerns about the pipeline and competition from Lilly. If the reorganization reduces internal bureaucracy and improves the speed of clinical, regulatory and commercial decisions, it could help Novo extract more value from its existing obesity portfolio while advancing next-generation treatments before the semaglutide patent cliff expected early next decade.
The company also has ***** ets that give a cultural and operational reset something concrete to build around. Wegovy was available in 52 countries by the end of 2025, while the company's higher-dose Wegovy achieved 20.7% weight loss in Phase 3 studies and its oral Wegovy achieved 16.6% weight loss. More recently, Wegovy received approval in China for MASH, expanding its potential beyond weight management and cardiovascular benefits into another large metabolic-disease market. If Novo Nordisk A/S (NYSE:NVO) can combine these products with better execution, the reset could support higher patient volumes and extend the commercial life of its GLP-1 franchise, helping defend revenue and cash flow despite pricing pressure.

#cultural #company #lilly

Brad Pitt and Ines de Ramon attended the women's and men's singles finals at the US Open in New York City on Sept. 12 and 13
Earlier this summer, the couple was also seen at a FIFA World Cup match in Los Angeles, and they stepped out for Taylor Swift and Travis Kelce's N.Y.C. wedding
Pitt's next movie, Heart of the Beast, is in theaters Sept. 25, and he also stars in The Further Mis-Adventures of Cliff Booth, which is in IMAX theaters Nov. 25 and releases on Netflix Dec. 23
Brad Pitt and Ines de Ramon are wrapping up their summer by taking in the country's top tennis competition.
Pitt, 62, and de Ramon, 33, attended the US Open men's singles tournament final on Sunday, Sept. 13, and were on hand to watch Germany's Alexander Zverev beat young American star Ben Shelton in four sets. (Kazakhstan's Elena Rybakina defeated Belarus' Aryna Sabalenka in three sets on Saturday, Sept. 12, to win the women's singles trophy, which Pitt and de Ramon also attended.). The actor, who wore a navy blue ***** on-down shirt with matching pants and a backwards ball cap, was seen holding de Ramon's knee as the two looked on intently during the match.

#sept #singles #brad #seen

The FedEx Cup Fall is here.
The 2026 Biltmore Championship, a new PGA Tour event in Asheville, North Carolina, kicks off Thursday. The Presidents Cup is set for next week outside of Chicago, but the first Tour event since the season-ending Tour Championship is up. The Cliffs at Walnut Grove will host the tournament. The layout is a par-71 measuring 7,249 yards.
Being a fall event, the purse is significantly smaller than most events from the regular season. The biggest name initially in the field, Justin Thomas, withdrew Sunday, too, but there are other notables set to take on the Biltmore.
Here's a look at the purse and prize money payouts for the 2026 Biltmore Championship, where $5 million is up for grabs in Asheville, North Carolina.
More: PGA Tour fall schedule includes 8 events, international competition, silly season

#biltmore #north

The Week 2 Houston-area and statewide Texas high school football scores from Saturday's games.
Aldine Davis 41, Bush 27
Cypress Park 18, Cypress Creek 12
George Ranch 14, Clear Springs 13
Kempner 32, Worthing 6
Manvel 75, Pasadena Memorial 0
Northbrook 29, Sharpstown 26
North Shore 23, Dallas South Oak Cliff 21
Texas City 21, Yates 14
Wheatley 70, Northside 0
Willowridge 52, Washington 23
SA Brennan 56, SA Taft 7
DeSoto 21, Duncanville 20,
Lockhart 20, Kyle Lehman 17
SA Harlandale 27, SA Edison 7

#creek

The FedExCup Fall series tees off at the The Cliffs at Walnut Cove next week as the PGA Tour's inaugural Biltmore Championship Asheville features plenty of big names.
The Blue Ridge Mountains will serve as a backdrop for U.S. Presidents Cup players Justin Thomas, Jacob Bridgeman and Jackson Koivun, who will be tuning up their games ahead of Medinah after getting the nod from captain Brandt Snedeker earlier in the month.
Also in the field are Billy Horschel and Lucas Glover, players No. 100 and No. 101 in the FedExCup points with less than a dozen events left to play this year. Those who sit inside the top 100 secure Tour cards for 2027, while players ranked 101st through 125th earn conditional status.
Following a couple weeks off, the Tour's action returns with plenty at stake, including a $5 million purse. Here's who else will be teeing off in Arden, North Carolina, next week.
2026 Biltmore Championship full field

#fedexcup #biltmore #fall

In 2024, Catalent tapped direct lenders for a $4.2 billion term loan to fund its acquisition by Novo Holdings. Last month, the drug manufacturer refinanced with a $4.1 billion syndicated loan that it says will cut its annual interest expense by about $100 million.
Catalent's move captures a shift under way in the leveraged finance market, according to a new report from DC Advisory. Redemptions from retail investors are contributing to the erosion of private credit's pricing advantage, creating an opening for banks to win refinancing business.
The problems in the retail private credit market show few signs of abating.
All the largest direct lenders, such as Ares, Apollo and KKR, also run business development companies, the most common form of credit fund aimed at individual investors, all under varying degrees of pressure to redeem investors.
PitchBook LCD reported on Wednesday that investors in Cliffwater's direct lending interval fund sought to redeem 16% of shares outstanding in the third quarter, down from 17% in the prior quarter.

#billion #private

The Princess of Wales looked as fresh, fabulous, and fashionable as ever on Friday morning as she arrived at the Royal Marsden Hospital in London.
Kate returned to the place where she received treatment and learned first-hand how funds raised through her National Three Peaks Challenge and ongoing support will transform holistic care for cancer patients across the UK.
Kate chose a stunning dress by Suzannah London (@ David Cliff / Kensington Palace)
The mother-of-three chose a trending colour for autumn - apple-green - in the form of a chic dress by Suzannah London. The beautiful design featured short sleeves, a subtle portrait neckline, **** on-down detailing, and an elegant front split.
The royal's dress is known as the 'Flippy Wiggle' and she has worn it once before (@ David Cliff / Kensington Palace)

#london #dress #kate #david

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.

#billion #novartis

Meghan Trainor celebrated her brother Justin's wedding to Alex with heartfelt posts and family photos
Justin Trainor, a producer and composer, has collaborated on Meghan's albums and lives near her in Los Angeles
Meghan has a close bond with her brothers, even previously setting them up on dates to find a "sister"
Meghan Trainor's brother is married!
The "All About That Bass" singer, 32, shared on Instagram Tuesday, Sept. 8 that her younger brother, Justin Trainor, 30, married his girlfriend, Alex, in a cliffside wedding. In her post, Trainor included behind-the-scenes photos as she got ready for the wedding and added sweet photos of her husband, Daryl Sabara, 34, and their two kids, Barry, 3, and Riley, 5, in their wedding best as all four walked down the aisle during the ceremony.

#wedding #brother #justin #angeles

No withdrawal order eliminates RMDs from a traditional IRA. Only Roth conversions, qualified charitable distributions, or never owning one in the first place can genuinely shrink them.
IRMAA surcharges hit Medicare premiums two years after the income that triggers them, jumping joint filers from $203 to $284 monthly by crossing $218,000 MAGI.
Letting an IRA compound untouched through your 60s forces larger RMDs at 73, often pushing retirees into higher brackets and through IRMAA cliffs simultaneously.
Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor)
A $2.1 million nest egg split evenly between a taxable brokerage account and a traditional IRA can throw off a six-figure income. What most retirees miss is that where each holding sits and when each dollar comes out determine whether Medicare surcharges and a swollen required minimum distribution eat that income a decade later.

#medicare #surcharges #retirees #magi

Vertiv, Applied Optoelectronics, and Innodata entered September well below their 2026 highs despite strong operating growth. The pullbacks do not make them interchangeable bargains. Vertiv Holdings Co. (NYSE:VRT) sells power and cooling, Applied Optoelectronics, Inc. (NASDAQ:AAOI) supplies optical transceivers, and Innodata Inc. (NASDAQ:INOD) provides data engineering and model-evaluation services.
Vertiv's second-quarter sales rose 24% to $3.27 billion, adjusted operating margin expanded 410 basis points to 22.6%, and adjusted free cash flow reached $925 million. The bull case is rising power and thermal content per AI rack. The bear case is project timing, supply congestion, and expectations built around long-duration demand. Insider Monkey counted 112 hedge funds holding Vertiv Holdings Co. (NYSE:VRT) in Q2, up from 96 in Q1. Cliff Asness's AQR Capital reported 2,686,683 shares, 0.5% more sequentially.
Applied Optoelectronics posted record revenue of $191.9 million, while 800G volume more than doubled from Q1. Management expects 800G and 1.6-terabit demand to exceed production capacity through mid-2027. That capacity ramp is the bull case; a 27.7% GAAP gross margin, a $22.8 million GAAP loss, customer concentration, and execution are the bear case. Fifty-four hedge funds held Applied Optoelectronics, Inc. (NASDAQ:AAOI), down from 55. Value Aligned Research disclosed 1,595,124 shares, 26% more sequentially.
Innodata's revenue grew 58% to $92.1 million and adjusted EBITDA rose 92% to $25.4 million. Its reusable data sets and evaluation work can expand margins, but large-customer dependence and rapidly changing model-training methods create risk. Twenty-five hedge funds held Innodata Inc. (NASDAQ:INOD), up from 20. Mitch Rubin's RiverPark Advisors reported 2,042 shares, 18% more than in Q1.
AAOI's August 14 short-interest settlement showed 10,421,985 shares sold short, equal to 12.81% of float, with 0.69 days to cover..The elevated short-float percentage signals substantial bearish positioning, while the low days-to-cover ratio suggests shorts could cover relatively quickly at recent trading volumes.Vertiv has the strongest cash generation, AAOI the sharpest capacity upside, and Innodata the lightest physical footprint. A buying opportunity exists only if margins, customer diversification, and cash conversion justify each stock's remaining expectations. The risks also differ in timing. Vertiv can lose on delayed data-center construction, AAOI can lose during the manufacturing ramp, and Innodata can lose when a major customer changes vendors or training methods. Investors should therefore avoid using distance from a high as valuation ******* ysis. Order conversion, gross-margin durability, customer concentration, and diluted share growth are the comparable checkpoints. The pullback improves entry prices, but only operating evidence can establish value. Balance-sheet resilience matters most when capacity plans meet a weaker cycle.

#innodata

After years as both an actor and a screenwriter, Cliff Dorfman is ready to set the stage for the next phase of his Hollywood career with his most personal project to date.
Dorfman, 58, rose to prominence in the 1990s with supporting roles on "Beverly Hills, 90210," among other shows. After shifting his focus to screenwriting, he wrote 14 episodes of HBO's "Entourage" and co-wrote the screenplay for the 2011 feature film "Warrior," starring Tom Hardy.
Buzz: Jameela Jamil Declares Botox A 'Prison' For Women: 'We Have Lost A Grip On Reality'
Despite those accomplishments, Dorfman says, he never had a chance to "understand my own story — and to survive it" until he wrote "Crime Family," his debut novel. Published in July, the 287-page thriller follows Chase Forman, a Hollywood writer who returns to his native Long Island, New York, to **** ist his family as his adoptive father's health and mental acuity decline.
Though Chase has spent most of his adulthood distancing himself from the Formans, he soon discovers that his family is part of an organized crime empire, with his adoptive mother, Helene, personally overseeing an international money-laundering operation. What follows is a gripping bicoastal chase as Chase and his family members become fugitives on the run from the FBI.

#family #dorfman #adoptive #cliff

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
The flagship private credit fund of Cliffwater LLC capped redemptions at 5% in Q3 after investors asked to redeem approximately 16% of shares.
Cliffwater Corporate Lending Fund told shareholders in a letter Thursday that it would fulfill approximately one-third of redemption requests, according to a shareholder letter seen by Bloomberg.
Cliffwater's Chief Executive Officer Stephen Nesbitt said in the letter the firm "remains committed to acting in the best interests," of its shareholders. Nesbitt added that investors who have requested cash since Q1 have received approximately 78% of capital.
Read Also:Brookfield Could Pull $600 Million From HomeServe in Debt Deal

#investors #benzinga

Sept 03, 2026, 1:00 pm EDT
Estimating the U.S. national debt as a percentage of economic growth seems to have become something of a national pastime—one that is moving beyond data nerds.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Blackstone and Cliffwater have seen redemption requests of about 10% and 16%, respectively, at their private credit funds.

#rights #reserved

Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below.
Ray Dalio is best known for founding one of the world's largest hedge funds, Bridgewater ****** ociates and for predicting the 2008 financial crisis. Now, Dalio has a new warning to share and it's one investors should heed (1).
While Dalio wrote a book laying out his concerns, he's also prepared a CliffNotes version published by Time and announced in an X post, stating, "I squeezed my explanation of the debt supply and demand problem into a 3-minute read, so it's my best, few-minute explanation of this problem (1)."
Jeff Bezos backs a platform that lets anyone invest in rental homes for as little as $100 — 6 ways to build wealth like a landlord without actually being one
JPMorgan sees gold hitting $5,000/oz by Q4 — and savvy investors are protecting their wealth with a tax-advantaged Gold IRA. Get your free guide from Priority Gold

#problem #minute #wealth

Most college golfers spend four years grinding on the mini-tours, hoping for a single shot at the big leagues. Tyler Jones just got that shot without waiting a single day. The reigning Southern Conference Men's Golfer of the Year has secured a sponsor exemption to the PGA Tour's inaugural Biltmore Championship. This marks a historic moment for Western Carolina University golf, as Jones becomes the first active Catamount to compete in a PGA Tour event, breaking a barrier that has stood for decades.
The details of this opportunity are specific and significant. According to the official release from catamountsports.com, Explore Asheville and Biltmore Estate granted the exemption. Three tournament victories during a breakthrough 2025-26 campaign earned Jones this spot. His standout performance came at the J.T. Poston Invitational, where he claimed an individual ***** le at the Waynesville Inn & Golf Club. Scheduled for Sept. 17-20 at The Cliffs at Walnut Cove, a Jack Nicklaus Signature Design course, the event itself is set there. For the first time since 1942, this tournament marks the PGA Tour's return to the mountains of western North Carolina. Coverage will be extensive, featuring Golf Channel, PGA TOUR LIVE on ESPN+, SiriusXM, and the PGA TOUR World Feed. Jones will also share the field with Western Carolina alumnus J.T. Poston, a four-time PGA Tour winner. That connection creates a full-circle moment for the program as it rises on the national stage.
The emotional weight of this achievement is clear in the words of the program leadership. Head coach Tim Eckberg, who is also an alumnus, spoke directly to the significance of the moment. "This is a massive day for Tyler and for Catamount golf," Eckberg said. He added that the opportunity fills him with pride, noting that the success stems from what J.T. Poston has accomplished and the hard work the current young men continue to put in. The coach emphasized that the program is finally being recognized for opportunities that were previously out of reach. Eckberg also highlighted the broader impact on the student-athlete. "He represents WCU exceptionally well as a student-athlete," the coach stated. "Tyler is an incredible talent, and he showed that throughout last season," Eckberg noted, adding that "His game is ready for this next challenge." The program also extended gratitude to the sponsors who made this possible. "A huge thank you goes to Biltmore and Explore Asheville for believing in Tyler and our program," the coach said. This support validates the years of development within the Catamount system.
From an insider perspective, this exemption signals a shift in how the Tour integrates local talent with regional events. The Biltmore Championship Asheville is designed to bridge the gap between the collegiate level and the professional tour in a specific geographic market. By bringing in a local star like Jones, the organizers ensure that the narrative of the tournament includes the very commu

Pfizer (NYSE: PFE) has faced several issues in recent years that have weighed on its share price. First, the company's coronavirus business isn't nearly as strong as it once was. Second, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant. Third, the pharmaceutical giant has faced clinical setbacks with otherwise promising pipeline candidates, including some it acquired. This problem has led to billions in impairment charges. Because of these headwinds (and others), Pfizer's shares have lagged broader equities over the past two years and have hovered below $30 apiece. Is it finally time to invest in the company? Let's see whether there is a rebound on the horizon.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Let's start with Pfizer's recent second-quarter update. The company's revenue increased by 1% year over year to $15 billion. While that top-line growth doesn't look impressive, it beat ***** yst estimates. On the bottom line, Pfizer's adjusted earnings per share were $0.77, slightly lower than the $0.78 reported in the prior-year quarter. Here too, Pfizer beat expectations. And it's important to highlight what drove the revenue and earnings beat.
The company noted that non-COVID revenue increased 5% year over year, while sales from launched and acquired products jumped 18%. This is great news for Pfizer. It suggests that newer (and acquired) products will help pull sales in the right direction over the medium term, while older medicines, especially within its coronavirus business, continue to lose steam.
Even with the progress Pfizer is making with relatively new launches, upcoming patent cliffs will be a major problem for the company. Consider, for instance, that Eliquis was the drugmaker's best-selling therapy during the second quarter. Pfizer's revenue from Eliquis came in at $2.4 billion, up 21% year over year. So, it arguably remains its single most important growth driver. Pfizer will have to launch more new drugs to fill the gap Eliquis will leave behind as it faces generic competition by the end of the decade. Can the company pull it off? My view is that it can.

#company #revenue #years